AlphaMark Advisors LLC Sells 565 Shares of Novo Nordisk A/S (NYSE:NVO)

AlphaMark Advisors LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 14.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,345 shares of the company’s stock after selling 565 shares during the period. AlphaMark Advisors LLC’s holdings in Novo Nordisk A/S were worth $429,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. Morgan Stanley raised its position in shares of Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after purchasing an additional 4,526,199 shares during the period. Folketrygdfondet raised its position in shares of Novo Nordisk A/S by 1.4% during the first quarter. Folketrygdfondet now owns 8,756,034 shares of the company’s stock worth $1,124,275,000 after purchasing an additional 124,770 shares during the period. Capital International Investors raised its position in shares of Novo Nordisk A/S by 22.3% during the fourth quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock worth $736,121,000 after purchasing an additional 1,297,536 shares during the period. Royal Bank of Canada raised its position in shares of Novo Nordisk A/S by 109.2% during the third quarter. Royal Bank of Canada now owns 3,643,061 shares of the company’s stock worth $331,300,000 after purchasing an additional 1,901,429 shares during the period. Finally, Natixis Advisors L.P. raised its position in Novo Nordisk A/S by 1.8% in the 4th quarter. Natixis Advisors L.P. now owns 3,052,406 shares of the company’s stock valued at $315,770,000 after buying an additional 55,333 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded up $2.68 during midday trading on Monday, hitting $145.42. 3,432,558 shares of the company’s stock were exchanged, compared to its average volume of 4,440,378. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $148.15. The company’s 50 day moving average price is $135.00 and its 200 day moving average price is $123.71. The firm has a market capitalization of $652.58 billion, a PE ratio of 50.14, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The company had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. As a group, analysts predict that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent research reports. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Argus lifted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. BMO Capital Markets reaffirmed an “outperform” rating and set a $163.00 price target on shares of Novo Nordisk A/S in a research report on Tuesday, June 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Monday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.